AVALO THERAPEUTICS, INC. Operating Expenses
AVALO THERAPEUTICS, INC. (AVTX) reported Operating Expenses of $9.33 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-11-14
- AVALO THERAPEUTICS, INC. operating expenses for the quarter ending 2019-09-30 was $9.33M, a 67.14% decline year-over-year.
- AVALO THERAPEUTICS, INC. operating expenses for the quarter ending 2019-06-30 was $10.43M, a 1.07% decline year-over-year.
- AVALO THERAPEUTICS, INC. operating expenses for the quarter ending 2019-03-31 was $12.43M, a 50.95% increase year-over-year.
- AVALO THERAPEUTICS, INC. operating expenses for the quarter ending 2018-12-31 was $10.48M, a 58.97% increase year-over-year.
- AVALO THERAPEUTICS, INC. operating expenses for fiscal 2018 was $57.64M, a 313.99% increase from fiscal 2017.
- AVALO THERAPEUTICS, INC. operating expenses for fiscal 2017 was $13.92M, a 19.21% decline from fiscal 2016.
- AVALO THERAPEUTICS, INC. operating expenses for fiscal 2016 was $17.23M, a 56.52% increase from fiscal 2015.
- AVALO THERAPEUTICS, INC. operating expenses for fiscal 2015 was $11.01M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | $9.33M 10-Q · filed 2019-11-14 | $19.75M derived: sum of 2 quarters · filed 2019-11-14 | $32.19M 10-Q · filed 2019-11-14 | $42.67M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2019-06-30 | $10.43M 10-Q · filed 2019-08-08 | $22.86M 10-Q · filed 2019-08-08 | $33.34M derived: sum of 3 quarters · filed 2019-08-08 | $61.72M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2019-03-31 | $12.43M 10-Q · filed 2019-05-09 | $22.91M derived: sum of 2 quarters · filed 2019-05-09 | $51.30M derived: sum of 3 quarters · filed 2019-11-14 | $61.84M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-12-31 | $10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $38.87M derived: sum of 2 quarters · filed 2019-11-14 | $49.40M derived: sum of 3 quarters · filed 2019-11-14 | $57.64M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $28.39M 10-Q · filed 2019-11-14 | $28.30M 10-Q · filed 2018-11-13 | $38.93M derived: sum of 2 quarters · filed 2019-11-14 | $47.16M 10-Q · filed 2019-11-14 | $46.80M 10-Q · filed 2018-11-13 | $53.75M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $10.54M 10-Q · filed 2019-08-08 | $10.52M 10-Q · filed 2018-08-09 | $18.78M 10-Q · filed 2019-08-08 | $18.50M 10-Q · filed 2018-08-09 | $25.37M derived: sum of 3 quarters · filed 2019-08-08 | $28.48M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $8.24M 10-Q · filed 2019-05-09 | $7.97M 10-Q · filed 2018-05-11 | $14.83M derived: sum of 2 quarters · filed 2019-05-09 | $17.94M derived: sum of 3 quarters · filed 2019-05-09 | $19.88M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $9.71M derived: sum of 2 quarters · filed 2019-03-18 | $11.64M derived: sum of 3 quarters · filed 2019-03-18 | $13.92M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $3.12M 10-Q · filed 2018-11-13 | $5.05M derived: sum of 2 quarters · filed 2018-11-13 | $7.33M 10-Q · filed 2018-11-13 | ||||
| 2017-06-30 | $1.93M 10-Q · filed 2018-08-09 | $4.22M 10-Q · filed 2018-08-09 | |||||
| 2017-03-31 | $2.28M 10-Q · filed 2018-05-11 | ||||||
| 2016-12-31 | $17.23M 10-K · filed 2018-04-02 | ||||||
| 2015-12-31 | $11.01M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |